Agripower France (ALAGP) H2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2026 earnings summary
2 Nov, 2026Executive summary
FY2025-26 marked a shift toward developing and investing in biomethane-injection plants; five new project stakes brought the portfolio to seven assets at 30 June 2026.
Consolidated revenue rose 161% to €11.5m, including initial biomethane sales; operating loss was €3.7m during the investment and deployment phase.
The portfolio had one operating plant, three Greenfield projects under construction, one further Greenfield project awaiting funding, and two Brownfield conversion projects.
Financial highlights
Consolidated revenue was €11.454m versus €4.5m pro forma in FY2024-25; biomethane sales contributed €4.6m, construction and development work €4.2m, and services €1.2m.
Parent-company revenue increased 125% to €8.3m, mainly from third-party construction contracts (€3.2m), work billed to project companies (€3.8m), and services and maintenance (€1.2m).
Parent-company operating loss narrowed to €2.1m from €4.0m, including a net €0.6m provision reversal; net loss improved to €1.9m from €3.9m.
Consolidated net loss was €4.4m versus €5.4m in FY2024-25; consolidated operating loss included a net €0.6m provision reversal.
Outlook and guidance
The priority is to secure near-term funding to cover working-capital needs while preserving asset value and continuing portfolio development.
2027 priorities include commissioning and ramping up installations; biomethane revenues are expected to grow as the six other units enter service.
Methélec bank refinancing, potentially including capacity expansion from 500 to 540 Nm3/h, is envisaged for 2027; other project commissioning schedules remain subject to funding availability.
At 1 July 2026, parent-company construction backlog was €14.6m; consolidated construction backlog was €7.0m, excluding services and SPV biomethane and electricity sales.
Latest events from Agripower France
- Strategic refocus on large biomethane projects, new contracts, and €8M capital increase planned.ALAGP
Trading update - Order backlog up 82% to €16.6M; H2 growth expected as biomethane projects accelerate.ALAGP
H1 2026 - Strategic pivot to biomethane injection, strong cash, and robust project pipeline drive growth.ALAGP
Trading Update - Transition year with €4.8M revenue, €4.9M net loss, and strategic shift to biomethane injection.ALAGP
H2 2024 - Revenue up 20%, losses halved, and biomethane projects fuel a strong €7M order backlog.ALAGP
H1 2025 - Losses narrowed and order book grew as focus shifted to biomethane injection projects.ALAGP
H2 2025